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In-field and abscopal response after short-
course radiation therapy in patients with
metastatic Merkel cell carcinoma
progressing on PD-1 checkpoint blockade:
a case series
Melody J. Xu1, Susan Wu1, Adil I. Daud2, Siegrid S. Yu3 and Sue S. Yom1*
Abstract
Background: Patients with metastatic Merkel cell carcinoma (mMCC) who experience disease progression on
immunotherapy have limited additional standard options. Given evidence of synergism between radiation
therapy (RT) and immunotherapy, two patients progressing on PD-1 inhibition were referred for short-course RT.
Case presentation: Two patients were found to have progressive mMCC on PD-1 inhibitor therapy and were
treated with single-fraction palliative RT. Both patients were observed to have local control at irradiated regions,
as well as durable abscopal response at unirradiated, out-of-field, sites of metastatic disease.
Conclusions: Short-course RT is a compelling strategy that could be a means to augment response in patients
with mMCC who show progression on immune checkpoint blockade. Ongoing clinical trials are investigating the
relationship between RT and immunotherapy in mMCC.
Keywords: Metastatic Merkel cell carcinoma, Abscopal response, PD-1 inhibition, Single-fraction radiation therapy,
Stereotactic body radiation therapy
Background
Merkel cell carcinoma (MCC) is a rare and aggressive skin
cancer. Considered an immunogenic tumor with high ex-
pression of neoantigens, MCC has been identified as a
promising candidate for immunotherapy trials [1–3].
Recently, two phase II trials for PD-1 and PD-L1 inhibition
in metastatic MCC (mMCC) reported encouraging object-
ive response rates of 56% in first line therapy and 32% in
second line therapy [4, 5]. However, a small proportion of
patients are either non-responders by 3 months or develop
progressive disease. mMCC patients who have failed initial
PD-1 immunotherapy have few additional treatment
options, with chemotherapy conferring less than 8 months
of progression-free survival (PFS) [6].
The abscopal effect, a phenomenon characterized by
regression of untreated metastatic lesions following local
therapy with radiation therapy (RT), is thought to be due to
an immune stimulus mediated by improved antigen presen-
tation and recruitment of CD8+ T cells after RT [7, 8]. A
growing body of literature suggests an increased rate of the
abscopal effect with the use of RT in combination with
immune checkpoint inhibitors [9–12]. Previously felt to be a
rare event following RT, the abscopal effect has been re-
ported in up to 50% of patients with melanoma, even after
progression on immunotherapy monotherapy [13]. While
additional clinical trials are underway to investigate the effect
of stereotactic body RT (SBRT) with immunotherapy in
melanoma (NCT02821182, NCT02407171, NCT02659540)
and non-small cell lung cancer (NCT02303990), the experi-
ence with mMCC is still developing.
We treated two patients who had progressive mMCC
on immunotherapy and observed an augmented, out-of-
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field abscopal response after single-fraction palliative
RT.
Case presentation a
Initial diagnosis and treatment
Mr. A was a 69-year-old man diagnosed with a
T3N1bM0, stage IIIB right upper back MCC in 2014. He
was treated with surgical excision and axillary lymph
node (LN) dissection, with pathology demonstrating
MCC. The tumor was positive for CK20 on immunohis-
tochemical staining and Merkel cell polyomavirus was
detected by polymerase chain reaction (PCR). The surgi-
cal margins were negative, but 2 of 29 LNs were found
to be involved with cancer. Thus, he received adjuvant
RT to a dose of 50 Gy in 25 fractions to the right axilla
and posterior chest wall.
Metastatic disease
A PET/CT two months later identified a hypermetabolic
peripancreatic abdominal mass measuring up to 11.3 cm
as well as a 1.1 cm left adrenal nodule. He was started
on pembrolizumab. On CT of the abdomen and pelvis
10 weeks later, the mass had enlarged to 15.8 cm, encas-
ing the celiac artery, hepatic artery, and splenic artery,
with a new satellite omental nodule and two new en-
larged para-aortic LNs. He began to develop symptoms
of severe bloating and constipation. Due to the rapidly
progressive and unresectable disease, he was referred for
palliative RT.
Radiation therapy
He received a single 8 Gy fraction of RT to the lower
portion of the mass (Fig. 1 Panel A, red). The radiation
field included the left adrenal nodule, omental nodule,
and two enlarged para-aortic LNs. The superior portion
of the tumor was untreated (Fig. 1 Panel B, blue). He tol-
erated the treatment well with near-immediate clinical
relief and no acute toxicities. He continued to receive
pembrolizumab.
Treatment outcome
Two weeks after RT, a CT scan showed a decrease in his
abdominal mass to 12 cm. At 2 months after RT, his ab-
dominal mass had markedly decreased to 3.5 cm in size,
with only residual pancreatic infiltration. By 8 months
after RT, he only had minimal soft tissue involvement of
the pancreatic body and tail. At 10 months after RT, he
had no evidence of residual mass in the pancreas. At
12 months after RT, his PET/CT demonstrated no evi-
dence of hypermetabolic malignancy (Fig. 1, Panel B).
He was discontinued from pembrolizumab therapy and
after stopping drug, was disease-free for another 17
months on surveillance scans. His most recent PET/CT
detected a 2 cm isolated thyroid mass that was biopsied
Fig. 1 Case A. Abdominal metastasis before and after RT with target volume outlined in red and untreated disease outlined in blue. Left (Panel
a): Coronal non-contrast CT scan obtained for RT planning demonstrating large abdominal mass. Right (Panel b): Coronal contrast CT obtained
12 months after RT demonstrating no evidence disease. Panel c: Timeline of therapy and disease status, with A and B corresponding to time
points depicted in Panel a and b above. c1 = cycle 1 of pembrolizumab. CT = computed tomography. RT = radiation therapy
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and confirmed to be mMCC. He has resumed pembroli-
zumab with RT to be given again based on response.
Case presentation B
Initial diagnosis and treatment
Mr. B was a 72-year-old man with a T1aN0M0, stage I
left thigh MCC. He was diagnosed in 2015 by an
excisional biopsy demonstrating MCC, which was CK20
positive. He had positive margins and subsequently
underwent a wide local excision and sentinel LN biopsy,
which showed no residual disease at the primary site
and no LN involvement. He did not receive adjuvant RT.
Metastatic disease
One year later, he noticed new left inguinal adenopathy,
and needle biopsy revealed MCC. A PET/CT scan dem-
onstrated bilateral hypermetabolic inguinal LNs and he
was started on pembrolizumab. At a 3-month re-staging
PET/CT, the level of fludeoxyglucose (FDG) uptake at
his inguinal LNs improved but he had new extensive
mediastinal adenopathy. He continued on pembrolizu-
mab for an additional 2 months, after which a PET/CT
demonstrated an increasing size and number (> 10) of
hypermetabolic LNs in the supraclavicular, mediastinal,
hilar, and upper abdominal nodal regions (Fig. 2). Due to
the number of involved nodal regions, he was not a can-
didate for surgical resection and was referred for RT.
Radiation therapy
He received a single fraction of 8 Gy of RT to his bulky
mediastinal and right hilar lymphadenopathy (Fig. 2, top
left). He tolerated the treatment well without acute tox-
icities and continued to receive pembrolizumab. His left
hilar lymphadenopathy and abdominal and inguinal
nodal disease remained unirradiated.
Treatment outcome
At 2 months after RT, he had increased FDG avidity at his
left inguinal LN but otherwise stable disease. At 4 months
after RT, he had a complete response at his untreated
supraclavicular and abdominal LN regions and decreased
metabolism in the mediastinum, bilateral hila, and un-
treated left inguinal region. At 6, 9, and 12 months after
RT, he had continued reduction and stabilization of hyper-
metabolism in his mediastinum, bilateral hila, and left in-
guinal region with no new areas of disease (Fig. 2, Panel B).
He remains on pembrolizumab.
Fig. 2 Case B. FDG-avid adenopathy before and after RT with target volume outlined in red and untreated disease outlined in blue. Left (Panel a): Coronal
pre-RT PET/CT demonstrating mediastinal FDG-avid adenopathy in the mediastinum and bilateral hila (top) and upper abdomen (bottom); not pictured:
supraclavicular adenopathy. Right (Panel b): Coronal PET/CT at 12 months after RT demonstrating radiographic response in the mediastinum and bilateral
hila (top) and radiographic response in the upper abdomen (bottom). Panel c: Timeline of therapy and disease status, with A and B corresponding to time
points depicted in Panel a and b above. c1 = cycle 1 of pembrolizumab. RT = radiation therapy. PET/CT = positron emission tomography/computed
tomography. FDG= fludeoxyglucose
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Discussion
Immune checkpoint blockade is an exciting treatment
option in mMCC, but a small proportion of patients do
not respond or experience disease progression despite
initial response. Herein, we describe two case examples
whereby the addition of short-course RT was associated
with subsequent improved immunotherapy response.
Both patients developed imaging evidence of disease pro-
gression with new and enlarging metastatic lesions within
the first 3 months of initiating pembrolizumab. Pseudopro-
gression was considered in both cases. Pseudoprogression
is a transient increased size of baseline tumor lesions due
to edema and immune cell infiltration, and is occasionally
used to describe delayed clinical responses in which initial
increases in tumor burden are followed by tumor regres-
sion in the setting of immunotherapy [14, 15]. While pseu-
doprogression/delayed response has only been observed in
two of 114 patients (1.8%) in the two phase II trials investi-
gating pembrolizumab in mMCC, it has been reported to
range from 2% in head and neck squamous cell carcinomas
[16] to 6–7% in non-small cell lung cancer and melanoma
[15, 17]. In patient A, pseudoprogression was unlikely due
to the increasingly infiltrative nature of his growing metas-
tasis, and a repeat scan in 3 months to rule out pseudopro-
gression was felt to be impractical given the high level of
pain and need for prompt intervention. Patient B, who was
found to have multiple new metastatic lesions increasing in
size and number on serial imaging evaluations, was ruled
out for pseudoprogression. Therefore, both patients were
considered to have true disease progression.
In the setting of disease progression, standard treat-
ment options are unfortunately limited and include cyto-
toxic chemotherapy or investigational trials. For the two
cases described, single fraction RT was attempted for
local control and to potentially enhance the opportunity
for systemic response to continued pembrolizumab.
These were the first two patients managed with this
exact sequence at our institution and both achieved
long-term local and systemic disease control.
We expected excellent local control and tolerability
with single-fraction RT in mMCC. In a retrospective re-
view of 26 mMCC patients treated with single-fraction
RT of 8 Gy, 94% of patients had objective responses with
a median PFS of 6.4 months [18]. Both patients tolerated
their treatment course very well without any notable
RT-associated toxicities. Consistent with prior reports of
single-fraction RT, the treated sites of disease had
marked response and durable local control.
Remarkably, both of our patients showed an out-of-field
effect following immunotherapy and RT, with augmented
response at unirradiated sites of disease. The timing of
response, 2 months after RT for patient A and 4 months
after RT for patient B, is consistent with what has been
reported in the literature on abscopal effect, with a median
time to response of 5 months [19]. Patient A’s untreated
superior tumor demonstrated a complete response after
10 months, leading to pembrolizumab discontinuation at
12 months and a subsequent 17-month disease-free inter-
val. In total, following RT patient A experienced a remark-
able disease response for 29 months including a long
treatment-free interval before developing a very recent 2
cm isolated thyroid recurrence. Patient B, who had diffuse
LN involvement that was progressing prior to RT, now
has a partial or complete response at multiple unirradiated
LN regions at 12 months after RT. He remains on pem-
brolizumab with stable disease and continues to do very
well clinically.
This is the first case series demonstrating an abscopal
effect from limited-field, single-fraction RT in mMCC
patients receiving immunotherapy. Two important clinical
trials will investigate the interaction between immunother-
apy and short-course RT in mMCC (NCT03071406 and
Alliance A091605). Our case series supports the rationale
of these trials. We believe there was synergism where the
radiation may have acted as an in situ vaccine, enhancing
the efficacy of the systemically administered immunother-
apy [20, 21]. Interestingly, Patient A was an initial im-
munotherapy non-responder and Patient B was an initial
responder with rapid re-progression, suggesting RT may
have synergistic effects with immunotherapy in both
patient populations.
We acknowledge that the findings of this case series re-
quire validation in larger, better-controlled cohorts and on-
going clinical trials. However, given that short-course RT is
exceptionally well-tolerated, highly effective for local con-
trol, and potentially synergistic with immunotherapy, it is a
compelling strategy that should be considered as a means
to augment response in patients with mMCC who are pro-
gressing on immune checkpoint blockade. Although cure
cannot be expected, our report demonstrates that a long
disease-free and treatment-free interval is achievable with
the addition of short-course RT in the setting of mMCC
progression on immunotherapy.
Conclusion
We report two cases of out-of-field abscopal response
following single-fraction RT in patients with mMCC
progressing on PD-1 checkpoint blockade. Ongoing clin-
ical trials are investigating the synergistic effects of RT
and immunotherapy in mMCC.
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